Vaccines as treatment strategies for relapsed prostate cancer: Approaches for induction of immunity Journal Article


Author: Slovin, S. F.
Article Title: Vaccines as treatment strategies for relapsed prostate cancer: Approaches for induction of immunity
Abstract: Prostate cancer is a important tumor in which to evaluate vaccine strategies. It is associated with two well-characterized serum biomarkers, prostate specific antigen (PSA) and prostatic acid phosphatase, which enables the investigator to monitor the progress of the disease. There are well-studied but less well-known glycoprotein and glycolipid antigens on the surface of prostate cancer cells that may function as targets for immune recognition and attack. Conventional treatments such as chemical castration are often poorly tolerated. When initiation of hormonal therapy is controversial, alternative therapies with minimal side effects are a desirable approach. Vaccines represent a means by which the immune system can be stimulated in order to affect an antitumor response by means of recruiting a variety of different effector arms of the immune system. The varying approaches toward vaccine construction as treatment strategies for relapsed prostate cancer are described.
Keywords: treatment outcome; review; cancer recurrence; salvage therapy; treatment indication; adenocarcinoma; animals; mice; cancer immunotherapy; neoplasm recurrence, local; dendritic cell; neoplasm proteins; transfection; prostate cancer; prostatic neoplasms; antigen presentation; cytokines; dendritic cells; molecular sequence data; antigens, neoplasm; cancer vaccine; cancer vaccines; neoplasm metastasis; gene therapy; thymidine kinase; rats; adjuvants, immunologic; vaccines, subunit; carbohydrate sequence; carbohydrates; viral proteins; oligonucleotides, antisense; gene transfer techniques; mucins; glycolipids; gangliosides; clinical trials, phase i; immunotherapy, active; humans; human; male; priority journal
Journal Title: Hematology/Oncology Clinics of North America
Volume: 15
Issue: 3
ISSN: 0889-8588
Publisher: Elsevier Inc.  
Date Published: 2001-06-01
Start Page: 477
End Page: 496
Language: English
DOI: 10.1016/s0889-8588(05)70227-6
PUBMED: 11525292
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 21 May 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Susan Slovin
    254 Slovin